Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1681
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19343343 | EXPRESSION SYSTEM FOR PRODUCT MANUFACTURING | Non-Final OA | Novel Biotechnology USA, Inc. |
| 19327026 | SYNTHETIC GENE CLUSTERS | Non-Final OA | The Regents of the University of California |
| 17763110 | NOVEL RECEPTORS HAVING A HETEROLOGOUS STOP TRANSFER SEQUENCE FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | Non-Final OA | The Regents of the University of California |
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17721798 | METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL USING HISTONE ACYLATION AS MARKERS | Non-Final OA | Hoffmann-La Roche Inc. |
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | Non-Final OA | Trustees of Boston University |
| 17309426 | METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 18279614 | METHOD FOR DETECTING MICRORNA IN BIOLOGICAL SAMPLE, COMPOSITION OF HYDROCHLORIDE OF NEUTRAL AMINO ACID, AND CONTAINER | Non-Final OA | Toray Industries, Inc. |
| 18266692 | METHODS FOR DETECTING HOMOGENOUS TARGETS IN A POPULATION WITH NEXT GENERATION SEQUENCING | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 18900481 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS | Non-Final OA | ACCUREDIT THERAPEUTICS (SUZHOU) CO., LTD. |
| 17298257 | SIRT2-ABLATED CHIMERIC T CELLS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17589081 | METHODS AND COMPOSITIONS FOR ASSESSING PROTEIN FUNCTION | Non-Final OA | University of Oregon |
| 17533007 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | Final Rejection | EDITAS MEDICINE, INC. |
| 18009557 | TANDEM ANELLOVIRUS CONSTRUCTS | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 17293802 | FUSOSOME COMPOSITIONS FOR T CELL DELIVERY | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18025136 | METHOD FOR PERFORMING GENE EDITING ON TARGET SITE IN CELL | Non-Final OA | BRL MEDICINE INC. |
| 18001340 | GENETIC MODIFICATION | Non-Final OA | Peter Biotherapeutics, Inc. |
| 17585694 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | Non-Final OA | Precision BioSciences, Inc. |
| 17632365 | Compositions and Methods for Modulation of Gene Expression | Non-Final OA | Altius Institute for Biomedical Sciences |
| 17708148 | Novel Cell Based Assay | Non-Final OA | Medical Diagnostics Laboratories, LLC |
| 17482307 | COMPOSITIONS AND METHODS FOR MONITORING IN REAL-TIME CONSTRUCTION AND BIOENGINEERING OF MAMMALIAN SYNTHETIC CHROMOSOMES | Non-Final OA | CarryGenes Bioengineering, LLC |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | Non-Final OA | CureVac AG |
| 17368957 | Comprehensive Platform for the DNA and RNA In Human Expression of Dimeric and Polymeric Immunoglobulin A Delivered in a Single Payload | Non-Final OA | Roger B. Swartz |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy